P467 Perception Gap between Patients with Inflammatory Bowel Disease (IBD) and Physicians in China: A Cross-sectional Study

Background The aim of the study was to assess the perception of inflammatory bowel disease (IBD) among Chinese patients and physicians. Methods Data in this cross-sectional study was collected from 6/2020 to 8/2020, which covered 24 provinces/cities in China and based on two surveys that was designed for collecting information from patients with Crohn’s disease (CD)/ulcerative colitis (UC) and the physicians. Results Surveys were completed by 1058 patients (601 CD and 457 UC patients) and 351 physicians (181 treating CD and 170 treating UC). For the control of disease symptoms over the past 12 months, physicians believed that 65.19% and 57.65% of CD and UC patients, respectively, were managed without affecting their quality of life. Meanwhile, 56.07% and 49.46% of CD and UC patients, respectively, reported that disease control did not affect their quality of life. Physicians estimated that 87.85% of CD and 88.24% of UC patients were satisfied with treatment results. And 86.36% of CD and 79.43% of UC patients were satisfied with the current medications. Physicians prescribed biologics for 69.52% of IBD patients, and 48.3% of IBD patients actually used them. Repeated medication (30.95%), diarrhea (27.95%) and abdominal pain (25.29%) were most frequently ranked as most bothersome symptoms by CD patients. For physicians, abdominal pain (42.54%) was the most bothersome symptoms, followed by repeated medication (23.76%) and diarrhea (17.13%). Regarding UC symptoms, 51.18% of physicians believed that bloody stool was the most bothersome symptom for patients, and 41.58% of patients held this view. The sense of urgency was concerned as one bothersome symptom by 19.69% patients, while only 4.12% of physicians held the same views (Fig 1). Regarding the efficacy evaluation, in view of the CD physicians, 42.5% of CD patients were believed achieving completely or mostly controlled, while from the patients’ perception, only 32.6% of CD patients agreed. Similarly, the proportion of UC patients who was believed by physicians that achieving completely or mostly controlled (40.0%) was also higher than that of UC patients who believed by themselves (Fig 2). Conclusion Most of the IBD patients and physicians were satisfied with the treatment results and the current medications. The disease control expectation of the patients was slightly more than that of the physicians. Further studies are needed to explore factors that associated with the treatment expectation of the patients.

Drug-related problems in head and neck cancer patients identified by repeated medication reviews on consecutive therapy cycles

Background Head and neck cancer (HNC) patients are particularly vulnerable to drug-related problems (DRPs) given the toxicity of concomitant chemoradiotherapy (CCRT). Objective To investigate the number and type of potential DRPs (pDRPs) in HNC outpatients undergoing five consecutive cycles of CCRT. Methods A single-centre, non-randomized, non-interventional, observational study was conducted at the Oncological Outpatient Clinic of the Center for Integrated Oncology at the University Hospital Bonn, Germany. Clinical pharmacists took a comprehensive medication history, documented laboratory data, assessed patients’ symptom burden, and retrospectively performed medication reviews at study entry and on the first day of each therapy cycle without any clinical intervention. Results In 26 patients, the mean number of pDRPs continuously increased during therapy course, from 4.8 (SD 2.7, range 2–12) at cycle 1 to 6.9 (SD 2.6, range 2–12) at cycle 5, with drug-drug interactions, adverse drug reactions, inappropriate durations of use, and inappropriate dosage intervals being the most common. Considering only new and recurrent pDRPs, the mean number was 4.3 (SD 2.3, range 2–9) at cycle 1 and lower in the further therapy course with an average of 1.3 (SD 1.7, range 0–7) at cycle 2 and 1.9 (SD 1.5, range 0–5) at cycle 5. The number of pDRPs was found to be associated with medication regimen complexity and health-related quality of life assessed in the first therapy cycle. Conclusion pDRPs frequently occurred in HNC outpatients demonstrating the need for pharmaceutical care. A methodological framework for repeated medication reviews was established, facilitating implementation into routine healthcare practice.